A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

@article{Kendra2015AMP,
  title={A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.},
  author={Kari Lynn Kendra and Ruth Plummer and Ravi Salgia and Mary R O'Brien and Elaine M Paul and Albert Benjamin Suttle and Natalie Compton and Chun-Fang Xu and Lone Harild Ottesen and Miguel Angel Villalona-Calero},
  journal={Molecular cancer therapeutics},
  year={2015},
  volume={14 2},
  pages={
          461-9
        }
}
This study was designed to evaluate the safety, pharmacokinetics, and clinical activity of pazopanib combined with paclitaxel to determine the recommended phase II dose in the first-line setting in patients with advanced solid tumors. Patients were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated regimen (MTR) of once daily pazopanib plus paclitaxel administered every 3 weeks at four dose levels (DL1-4). Safety, pharmacokinetics, pharmacogenetics, and disease… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Developments in targeted therapy in melanoma.

  • European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.

  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma

  • Clinical Medicine Insights. Oncology
  • 2013
VIEW 2 EXCERPTS

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 3 EXCERPTS

A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: interim analysis

JP Fruehauf, B Alger, +3 authors T Chuang
  • J Clin Oncol 30;2012;(May
  • 2012
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…